Arance A et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination.  J Clin Oncol 2022;[Online ahead of print]. Abstract

Blackburn SD et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10(1):29-37. Abstract

Burova E et al. Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice. Mol Cancer Ther 2017;16(5):861-70. Abstract

Burova E et al. Preclinical development of the anti-LAG-3 antibody REGN3767: Characterization and activity in combination with the anti-PD-1 antibody cemiplimab in human PD-1xLAG-3-knockin mice. Mol Cancer Ther 2019;18(11):2051-62. Abstract

Comito F et al. Emerging novel therapeutic approaches for treatment of advanced cutaneous melanoma. Cancers (Basel) 2022;14(2):271. Abstract

Haanen JBAG et al. Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial. ESMO 2022;Abstract LBA3.

Hack SP et al. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: Challenges and opportunities. Front Immunol 2020;11:598877. Abstract

Hamid O et al. Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel). ESMO 2022;Abstract 790M0.

Long GV et al. Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047). ASCO 2022;Abstract 360385.<

Long L et al. The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy. Genes Cancer 2018;9(5-6):176-89. Abstract

Middleton MR et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18(1):158-66. Abstract

Paley MA et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012;338(6111):1220-5. Abstract

Sarnaik AA et al. Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. ASCO 2020;Abstract 10006.<

Tawbi HA et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022;386(1):24-34. Abstract

Wherry EJ. T cell exhaustion. Nat Immunol 2011;12(6):492-9. Abstract

Wolchok JD et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. ASCO 2021;Abstract 9506.<

Wolchok JD et al. Reply to T. Olivier et al. J Clin Oncol 2022;40(14):1597-8. Abstract